Use and cost of erythropoiesis-stimulating agents in patients with cancer

By Daniel Gregory   Hurley Dana   Whyte Joanna L.   Willey Vincent   Wilson Marcus   Kallich Joel  

Current Medical Research and Opinion, Vol. 25, Iss. 7, 2009-07 ,pp. : 1775-1784

Informa Healthcare

Access to resources Recommend Favorite

The Effect of Erythropoiesis-Stimulating Agents in Patients with Therapy-Refractory Autoimmune Hemolytic Anemia

By  

Transfusion Medicine and Hemotherapy, Vol. 41, Iss. 6, 2014-09 ,pp. : 462-468

Karger

Access to resources Recommend Favorite

Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents*

By Silver M. R.   Geronemus R.   Krause M.   Chen C. Y.   Kewalramani R.   Stehman-Breen C.  

Current Medical Research and Opinion, Vol. 25, Iss. 1, 2009-01 ,pp. : 123-131

Informa Healthcare

Access to resources Recommend Favorite

Complete correction of anemia by erythropoiesis-stimulating agents is associated with insulin resistance in hemodialysis patients

By Biolo Gianni   Guarnieri Gianfranco   Barazzoni Rocco   Panzetta Giovanni  

Clinical and Experimental Medicine, Vol. 11, Iss. 3, 2011-09 ,pp. : 181-187

Springer Publishing Company

Access to resources Recommend Favorite

Effect of Synthetic Vitamin E-Bonded Membrane on Responsiveness to Erythropoiesis-Stimulating Agents in Hemodialysis Patients: A Pilot Study

By  

Nephron Clin Pract, Vol. 115, Iss. 1, 2010-03 ,pp. : c82-c89

Karger

Access to resources Recommend Favorite